October PharmaE (OCPH) Stock Overview
Manufactures and sells pharmaceutical products in Egypt. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
OCPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
October Pharma S.A.E Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م192.13 |
| 52 Week High | ج.م249.88 |
| 52 Week Low | ج.م90.02 |
| Beta | 0.15 |
| 1 Month Change | -5.52% |
| 3 Month Change | -7.17% |
| 1 Year Change | 78.93% |
| 3 Year Change | 92.13% |
| 5 Year Change | 284.26% |
| Change since IPO | 3,944.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 1.1% | 5.2% | 2.7% |
| 1Y | 78.9% | 88.7% | 41.7% |
Return vs Industry: OCPH underperformed the EG Pharmaceuticals industry which returned 88.5% over the past year.
Return vs Market: OCPH exceeded the EG Market which returned 42% over the past year.
Price Volatility
| OCPH volatility | |
|---|---|
| OCPH Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in EG Market | 8.5% |
| 10% least volatile stocks in EG Market | 3.0% |
Stable Share Price: OCPH has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: OCPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Hesham Abdul Soliman | octoberpharma.com |
October Pharma S.A.E manufactures and sells pharmaceutical products in Egypt. The company provides human medicines in the form of capsules, tablets, suppositories, syrup, and drops for internal and sprays and inhalers for external use. October Pharma S.A.E was incorporated in 1987 is based in Cairo, Egypt.
October Pharma S.A.E Fundamentals Summary
| OCPH fundamental statistics | |
|---|---|
| Market cap | ج.م2.31b |
| Earnings (TTM) | ج.م165.09m |
| Revenue (TTM) | ج.م1.46b |
Is OCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCPH income statement (TTM) | |
|---|---|
| Revenue | ج.م1.46b |
| Cost of Revenue | ج.م841.18m |
| Gross Profit | ج.م620.57m |
| Other Expenses | ج.م455.48m |
| Earnings | ج.م165.09m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.76 |
| Gross Margin | 42.45% |
| Net Profit Margin | 11.29% |
| Debt/Equity Ratio | 64.0% |
How did OCPH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 07:21 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
October Pharma S.A.E is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.